A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

This study has been completed.

Sponsor:
Merck Sharp & Dohme Corp.

Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

ClinicalTrials.gov Identifier:
NCT00293267

First received: February 14, 2006
Last updated: September 4, 2015
Last verified: September 2015
History of Changes

Purpose

This study will investigate the safety and efficacy of raltegravir as a therapy for HIV-infected patients failing current therapy with 3-class antiviral resistance.

Condition	Intervention	Phase
HIV Infections	Drug: raltegravir potassium Drug: Comparator: Placebo	Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Official Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed Oral Antiviral Therapies

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS Potassium

Drug Information available for: Raltegravir Raltegravir potassium

U.S. FDA Resources

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:

- Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 [Time Frame: 16 Weeks] [Designated as safety issue: No]
  Percentage of participants who achieved HIV RNA <400 copies/mL at Week 16
- Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 48 [Time Frame: 48 Weeks] [Designated as safety issue: No]
  Percentage of participants who achieved HIV RNA <400 copies/mL at Week 48
- Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <400 Copies/mL [Time Frame: 156 Weeks] [Designated as safety issue: No]
  Percentage of participants who achieved HIV RNA <400 copies/mL at Week 156
- Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <400 Copies/mL [Time Frame: 240 Weeks] [Designated as safety issue: No]
  Percentage of participants who achieved HIV RNA <400 Copies/mL at Week 240

Secondary Outcome Measures:

- Percentage of Participants Achieving HIV RNA <50 Copies/mL at Week 16 [Time Frame: 16 Weeks] [Designated as safety issue: No]
  Percentage of participants who achieved HIV RNA <50 copies/mL at Week 16
- Percentage of Participants Achieving HIV RNA <50 Copies/mL at Week 48 [Time Frame: 48 Weeks] [Designated as safety issue: No]
  Percentage of participants who achieved HIV RNA <50 copies/mL at Week 48
- Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <50 Copies/mL [Time Frame: 156 weeks] [Designated as safety issue: No]
  Percentage of participants who achieved HIV RNA <50 copies/mL at Week 156
- Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <50 Copies/mL [Time Frame: 240 weeks] [Designated as safety issue: No]
  Percentage of participants who achieved HIV RNA <50 copies/mL at Week 240
- Double-Blind Extension - Week 156: Percentage of Participants Without Loss of Virologic Response [Time Frame: 156 weeks] [Designated as safety issue: No]
  For participants with confirmed HIV RNA levels <50 copies/mL on 2 consecutive visits, loss of virologic response is the occurrence of the first value >50 copies/mL or loss to follow-up; participants who never achieved HIV RNA <50 copies/mL on 2 consecutive visits are also considered as having loss of virologic response. Events are the numbers of participants with loss of virologic response versus the numbers of participants with no loss of virologic response (event free).
- Change From Baseline in HIV RNA (log10 Copies/mL) at Week 16 [Time Frame: Baseline and Week 16] [Designated as safety issue: No]
  Mean change from baseline at Week 16 in HIV RNA (log10 copies/mL)
- Change From Baseline in HIV RNA (log10 Copies/mL) at Week 48 [Time Frame: Baseline and Week 48] [Designated as safety issue: No]
  Mean change from baseline at Week 48 in HIV RNA (log10 copies/mL)
- Double-Blind Extension - Week 156: Change From Baseline in HIV RNA (log10 Copies/mL) [Time Frame: Baseline and Week 156] [Designated as safety issue: No]
  Mean change from baseline at Week 156 in HIV RNA (log10 copies/mL)
- Open-Label Extension - Week 240: Change From Baseline in HIV RNA (log10 Copies/mL) [Time Frame: Baseline and Week 240] [Designated as safety issue: No]
  Mean change from baseline at Week 240 in HIV RNA (log10 copies/mL)
- Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 16 [Time Frame: Baseline and Week 16] [Designated as safety issue: No]
  Mean change from baseline at Week 16 in CD4 Cell Count (cells/mm^3)

- Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 48 [Time Frame: Baseline and Week 48] [Designated as safety issue: No]

  Mean change from baseline at Week 48 in CD4 Cell Count (cells/mm^3)

- Double-Blind Extension - Week 156: Change From Baseline in CD4 Cell Count (Cells/mm^3) [Time Frame: Baseline and Week 156] [Designated as safety issue: No]

  Mean change from baseline at Week 156 in CD4 Cell Count (cells/mm^3)

- Open-Label Extension - Week 240: Change From Baseline in CD4 Cell Count (Cells/mm^3) [Time Frame: Baseline and Week 240] [Designated as safety issue: No]

  Mean change from baseline at Week 240 in CD4 Cell Count (cells/mm^3)

Enrollment:	352
Study Start Date:	February 2006
Study Completion Date:	May 2011
Primary Completion Date:	August 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 raltegravir potassium	Drug: raltegravir potassium Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks. Other Name: ISENTRESS™
Placebo Comparator: 2 Placebo	Drug: Comparator: Placebo Placebo b.i.d. p.o. with optimized background therapy. Treatment period of 48 weeks.

Detailed Description:

The primary double-blind study of raltegravir versus placebo was extended to 156 weeks and was followed by an open-label raltegravir phase in which continuing participants from both the raltegravir and placebo groups received open-label raltegravir for an additional 84 weeks for a maximum duration of up to 240 weeks. Participants who had viral failure after Week 16 may have received open-label raltegravir until Week 240.

Eligibility

Ages Eligible for Study:	16 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

- Patient must be HIV positive with HIV RNA values that are within ranges required by the study
- Patient must have documented failure of certain antiretroviral therapy
- Patient must be on the same antiretroviral therapy for at least the past two months

Exclusion Criteria:

- Patient is less than 16 years old
- Additional study criteria will be discussed and identified by the study doctor

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00293267

Sponsors and Collaborators

Merck Sharp & Dohme Corp.

Investigators

Study Director: Medical Monitor Merck Sharp & Dohme Corp.

More Information

Publications:

Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002.

Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975.

Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978.

Responsible Party:	Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:	NCT00293267 History of Changes
Other Study ID Numbers:	**0518-018** 2005_096
Study First Received:	February 14, 2006
Results First Received:	August 18, 2009
Last Updated:	September 4, 2015
Health Authority:	France: Ministry of Health

Keywords provided by Merck Sharp & Dohme Corp.:
Treatment Experienced

ClinicalTrials.gov processed this record on March 10, 2016

TO TOP

For Patients and Families | For Researchers | For Study Record Managers

HOME RSS FEEDS SITE MAP TERMS AND CONDITIONS DISCLAIMER CONTACT NLM HELP DESK

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

This study has been completed.

Sponsor:
Merck Sharp & Dohme Corp.

Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

ClinicalTrials.gov Identifier:
NCT00293267

First received: February 14, 2006
Last updated: September 4, 2015
Last verified: September 2015
History of Changes

Results First Received: August 18, 2009

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Investigator); Primary Purpose: Treatment
Condition:	HIV Infections
Interventions:	Drug: raltegravir potassium Drug: Comparator: Placebo

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

Phase 3; First Patient In: Mar 2006; Last Patient Last Visit (LPLV) Week 48: Aug 2007; 61 of 63 sites in Australia, Belgium, Denmark, France, Germany, Italy, Peru, Portugal, Spain, Switzerland, Taiwan, Thailand randomized patients. Extension Study LPLV Week 240: June 2011

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment

Patients failed prior antiretroviral therapy (HIV RNA >1000 copies/mL), and had documented resistance to at least one drug in each class of licensed oral antiretroviral therapy (Nucleoside Reverse Transcriptase inhibitors, Non-Nucleoside Reverse Transcriptase inhibitors and Protease Inhibitors). All patients must have met laboratory criteria.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.
Placebo + OBT	No text entered.

Participant Flow for 4 periods

Period 1: Primary Study - Double-Blind Week 0-48

	Raltegravir 400 mg b.i.d. + OBT	Placebo + OBT
STARTED	**234**	**118**
Treated	**232**	**118**
Continuing in Double-Blind	**193** [1]	**50**
COMPLETED	**193**	**50**
NOT COMPLETED	**41**	**68**
Never Treated	**2**	**0**
Adverse Event	**1**	**1**
Death	**3**	**3**
Lack of Efficacy	**0**	**2**
Lost to Follow-up	**1**	**1**
Withdrawal by Subject	**1**	**1**
Entered OLPVF Phase	**33**	**60**

[1] Excludes participants who entered the open-label post virological failure (OLPVF) phase

Period 2: Extension - Double-Blind Week 49-156

	Raltegravir 400 mg b.i.d. + OBT	Placebo + OBT
STARTED	**191** [1]	**50**
COMPLETED	**139**	**35**
NOT COMPLETED	**52**	**15**
Adverse Event	**1**	**4**
Lack of Efficacy	**7**	**1**
Lost to Follow-up	**4**	**0**
Withdrawal by Subject	**13**	**4**
Death	**3**	**0**
Participant relocated or site terminated	**2**	**0**
Other Reason	**7**	**0**
Entered OLPVF Phase	**15**	**6**

[1] 2 participants who completed Week 48 did not enter the extension study

Period 3: Extension - Open-Label Week 157-240

	Raltegravir 400 mg b.i.d. + OBT	Placebo + OBT
STARTED	131 [1]	28 [2]
COMPLETED	111	26
NOT COMPLETED	20	2
Adverse Event	5	0
Lack of Efficacy	7	0
Lost to Follow-up	1	0
Withdrawal by Subject	2	1
Participant relocated or site terminated	2	0
Other Reason	3	1

[1] 8 of 139 participants who completed the double-blind phase did not enter this open-label phase
[2] 7 of 35 participants who completed the double-blind phase did not enter this open-label phase

Period 4: Open-Label Post Virologic Failure Phase

	Raltegravir 400 mg b.i.d. + OBT	Placebo + OBT
STARTED	48 [1]	66 [1]
COMPLETED	15	29
NOT COMPLETED	33	37
Adverse Event	2	3
Lack of Efficacy	23	19
Withdrawal by Subject	2	4
Lost to Follow-up	2	2
Laboratory Adverse Event	0	2
Participant Moved or Site Terminated	0	2
Other Reason	4	5

[1] Number of participants who failed treatment and consented to enter the OLPVF phase

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.
Placebo + OBT	No text entered.
Total	Total of all reporting groups

Baseline Measures

	Raltegravir 400 mg b.i.d. + OBT	Placebo + OBT	Total
Number of Participants [units: participants]	**232**	**118**	**350**
Age [units: Years] Mean (Full Range)	**46.1 (16 to 74)**	**43.7 (19 to 64)**	**45.3 (16 to 74)**
Gender [units: participants]			
Female	**37**	**15**	**52**
Male	**195**	**103**	**298**
Race/Ethnicity, Customized [units: participants]			
White	**174**	**96**	**270**
Black	**18**	**5**	**23**
Asian	**14**	**5**	**19**
Hispanic	**6**	**1**	**7**
Other	**20**	**11**	**31**
Cluster of Differentiation 4 (CD4) Cell Count [units: cells/mm^3] Mean (Full Range)	**156 (1 to 792)**	**153 (3 to 759)**	**155 (1 to 792)**
Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) [units: copies/mL] Geometric Mean (Full Range)	**40519 (441 to 750000)**	**31828 (200 to 750000)**	**37352 (200 to 750000)**

Outcome Measures

Hide All Outcome Measures

1. Primary: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 [Time Frame: 16 Weeks]

Measure Type	Primary
Measure Title	Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16
Measure Description	Percentage of participants who achieved HIV RNA <400 copies/mL at Week 16
Time Frame	16 Weeks
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.
Placebo + OBT	No text entered.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	**Placebo + OBT**
Number of Participants Analyzed [units: participants]	**229**	**117**
Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 [units: Percentage of Participants] Number (95% Confidence Interval)	**77.7 (71.8 to 82.9)**	**41.0 (32.0 to 50.5)**

No statistical analysis provided for Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16

2. Primary: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 48 [Time Frame: 48 Weeks]

Measure Type	Primary
Measure Title	Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 48
Measure Description	Percentage of participants who achieved HIV RNA <400 copies/mL at Week 48
Time Frame	48 Weeks
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants who experienced virologic failure after Week 16 are also counted as treatment failures for the subsequent virologic efficacy analyses.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.
Placebo + OBT	No text entered.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	Placebo + OBT
Number of Participants Analyzed [units: participants]	**231**	**118**
Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 48 [units: Percentage of Participants] Number (95% Confidence Interval)	**73.6 (67.4 to 79.2)**	**36.4 (27.8 to 45.8)**

No statistical analysis provided for Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 48

3. Primary: Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <400 Copies/mL [Time Frame: 156 Weeks]

Measure Type	Primary
Measure Title	Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <400 Copies/mL
Measure Description	Percentage of participants who achieved HIV RNA <400 copies/mL at Week 156
Time Frame	156 Weeks
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

The analysis population was based on a non-completer equals failure approach where missing values for participants who discontinued the study for any reason were considered treatment failures.

Participants who experienced virologic failure after Week 16 are counted also as treatment failures for the subsequent virologic efficacy analyses.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.
Placebo + OBT	No text entered.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	Placebo + OBT
Number of Participants Analyzed [units: participants]	**232**	**117**
Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <400 Copies/mL [units: Percentage of Participants] Number (95% Confidence Interval)	**57.3 (50.7 to 63.8)**	**25.6 (18.0 to 34.5)**

No statistical analysis provided for Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <400 Copies/mL

4. Primary: Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <400 Copies/mL [Time Frame: 240 Weeks]

Measure Type	Primary
Measure Title	Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <400 Copies/mL
Measure Description	Percentage of participants who achieved HIV RNA <400 Copies/mL at Week 240
Time Frame	240 Weeks
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The analysis population was based on a non-completer equals failure approach where missing values for participants who discontinued the study for any reason were considered treatment failures. Participants who experienced virologic failure after Week 16 are also counted as treatment failures for the subsequent virologic efficacy analyses.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	Raltegravir 400 mg b.i.d plus OBT includes all participants initially randomized to raltegravir. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants continued to receive raltegravir plus OBT until Week 240.
Placebo + OBT	Placebo plus OBT includes all participants initially randomized to placebo. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants received raltegravir plus OBT until Week 240.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	**Placebo + OBT**
Number of Participants Analyzed [units: participants]	**232**	**118**
Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <400 Copies/mL [units: Percentage of Participants] Number (95% Confidence Interval)	**45.3 (38.7 to 51.9)**	**20.3 (13.5 to 28.7)**

No statistical analysis provided for Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <400 Copies/mL

5. Secondary: Percentage of Participants Achieving HIV RNA <50 Copies/mL at Week 16 [Time Frame: 16 Weeks]

Measure Type	Secondary
Measure Title	Percentage of Participants Achieving HIV RNA <50 Copies/mL at Week 16
Measure Description	Percentage of participants who achieved HIV RNA <50 copies/mL at Week 16
Time Frame	16 Weeks

Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.
Placebo + OBT	No text entered.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	**Placebo + OBT**
Number of Participants Analyzed [units: participants]	**229**	**117**
Percentage of Participants Achieving HIV RNA <50 Copies/mL at Week 16 [units: Percentage of Participants] Number (95% Confidence Interval)	**61.6 (54.9 to 67.9)**	**33.3 (24.9 to 42.6)**

No statistical analysis provided for Percentage of Participants Achieving HIV RNA <50 Copies/mL at Week 16

6. Secondary: Percentage of Participants Achieving HIV RNA <50 Copies/mL at Week 48 [Time Frame: 48 Weeks]

Measure Type	Secondary
Measure Title	Percentage of Participants Achieving HIV RNA <50 Copies/mL at Week 48
Measure Description	Percentage of participants who achieved HIV RNA <50 copies/mL at Week 48
Time Frame	48 Weeks
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants who experienced virologic failure after Week 16 are also counted as treatment failures for the subsequent virologic efficacy analyses.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.
Placebo + OBT	No text

	entered.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	Placebo + OBT
Number of Participants Analyzed [units: participants]	**231**	**118**
Percentage of Participants Achieving HIV RNA <50 Copies/mL at Week 48 [units: Percentage of Participants] Number (95% Confidence Interval)	**64.5 (58.0 to 70.7)**	**31.4 (23.1 to 40.5)**

No statistical analysis provided for Percentage of Participants Achieving HIV RNA <50 Copies/mL at Week 48

7. Secondary: Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <50 Copies/mL [Time Frame: 156 weeks]

Measure Type	Secondary
Measure Title	Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <50 Copies/mL
Measure Description	Percentage of participants who achieved HIV RNA <50 copies/mL at Week 156
Time Frame	156 weeks
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants who experienced virologic failure after Week 16 are also counted as treatment failures for the subsequent virologic efficacy analyses.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.
Placebo + OBT	No text entered.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	Placebo + OBT
Number of Participants Analyzed [units: participants]	**232**	**117**
Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <50 Copies/mL [units: Percentage of Participants] Number (95% Confidence Interval)	**53.4 (46.8 to 60.0)**	**25.6 (18.0 to 34.5)**

No statistical analysis provided for Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <50 Copies/mL

8. Secondary: Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <50 Copies/mL [Time Frame: 240 weeks]

Measure Type	Secondary
Measure Title	Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <50 Copies/mL
Measure Description	Percentage of participants who achieved HIV RNA <50 copies/mL at Week 240
Time Frame	240 weeks
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants who experienced virologic failure after Week 16 are also counted as treatment failures for the subsequent virologic efficacy analyses.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	Raltegravir 400 mg b.i.d plus OBT includes all participants initially randomized to raltegravir. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants continued to receive raltegravir plus OBT until Week 240.
Placebo + OBT	Placebo plus OBT includes all participants initially randomized to placebo. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants received raltegravir plus OBT until Week 240.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	**Placebo + OBT**
Number of Participants Analyzed [units: participants]	**232**	**118**
Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <50 Copies/mL [units: Percentage of Participants] Number (95% Confidence Interval)	**42.2 (35.8 to 48.9)**	**18.6 (12.1 to 26.9)**

No statistical analysis provided for Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <50 Copies/mL

9. Secondary: Double-Blind Extension - Week 156: Percentage of Participants Without Loss of Virologic Response [Time Frame: 156 weeks]

Measure Type	Secondary
Measure Title	Double-Blind Extension - Week 156: Percentage of Participants Without Loss of Virologic Response
Measure Description	For participants with confirmed HIV RNA levels <50 copies/mL on 2 consecutive visits, loss of virologic response is the occurrence of the first value >50 copies/mL or loss to follow-up; participants who never achieved HIV RNA <50 copies/mL on 2 consecutive visits are also considered as having loss of virologic response. Events are the numbers of participants with loss of virologic response versus the numbers of participants with no loss of virologic response (event free).
Time Frame	156 weeks

Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants who experienced virologic failure after Week 16 are also counted as treatment failures for the subsequent virologic efficacy analyses.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.
Placebo + OBT	No text entered.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	**Placebo + OBT**
Number of Participants Analyzed [units: participants]	**232**	**118**
Double-Blind Extension - Week 156: Percentage of Participants Without Loss of Virologic Response [units: Percentage of Participants]	**47.4**	**24.6**

No statistical analysis provided for Double-Blind Extension - Week 156: Percentage of Participants Without Loss of Virologic Response

10. Secondary: Change From Baseline in HIV RNA (log10 Copies/mL) at Week 16 [Time Frame: Baseline and Week 16]

Measure Type	Secondary
Measure Title	Change From Baseline in HIV RNA (log10 Copies/mL) at Week 16
Measure Description	Mean change from baseline at Week 16 in HIV RNA (log10 copies/mL)
Time Frame	Baseline and Week 16
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Observed mean change from baseline in log10 plasma HIV RNA calculated using conventional imputation (replace <400 copies by 400 copies if signal detected; 200 copies if not detected); Missing values: baseline carry-forward for all failures/discontinued due to lack of efficacy

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.

Placebo + OBT	No text entered.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	Placebo + OBT
Number of Participants Analyzed [units: participants]	**231**	**118**
Change From Baseline in HIV RNA (log10 Copies/mL) at Week 16 [units: HIV RNA (log10 copies/mL)] Mean (95% Confidence Interval)	**-1.85 (-1.97 to -1.73)**	**-0.78 (-0.97 to -0.59)**

No statistical analysis provided for Change From Baseline in HIV RNA (log10 Copies/mL) at Week 16

11. Secondary: Change From Baseline in HIV RNA (log10 Copies/mL) at Week 48 [Time Frame: Baseline and Week 48]

Measure Type	Secondary
Measure Title	Change From Baseline in HIV RNA (log10 Copies/mL) at Week 48
Measure Description	Mean change from baseline at Week 48 in HIV RNA (log10 copies/mL)
Time Frame	Baseline and Week 48
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Observed mean change from baseline in log10 plasma HIV RNA calculated using conventional imputation (replace <400 copies by 400 copies if signal detected; 200 copies if not detected); Missing values: baseline carry-forward for all failures/discontinued due to lack of efficacy Participants with virologic failure after Week 16 = treatment failures

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.
Placebo + OBT	No text entered.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	Placebo + OBT
Number of Participants Analyzed [units: participants]	**231**	**118**
Change From Baseline in HIV RNA (log10 Copies/mL) at Week 48 [units: HIV RNA (log10 copies/mL)] Mean (95% Confidence Interval)	**-1.67 (-1.81 to -1.54)**	**-0.68 (-0.86 to -0.50)**

No statistical analysis provided for Change From Baseline in HIV RNA (log10 Copies/mL) at Week 48

12. Secondary: Double-Blind Extension - Week 156: Change From Baseline in HIV RNA (log10 Copies/mL) [Time Frame: Baseline and Week 156]

Measure Type	Secondary
Measure Title	Double-Blind Extension - Week 156: Change From Baseline in HIV RNA (log10 Copies/mL)
Measure Description	Mean change from baseline at Week 156 in HIV RNA (log10 copies/mL)
Time Frame	Baseline and Week 156
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Observed mean change from baseline in log10 plasma HIV RNA calculated using conventional imputation (replace <400 copies by 400 copies if signal detected; 200 copies if not detected); Missing values: baseline carry-forward for all failures/discontinued due to lack of efficacy Participants with virologic failure after Week 16 = treatment failures

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.
Placebo + OBT	No text entered.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	**Placebo + OBT**
Number of Participants Analyzed [units: participants]	**207**	**107**
Double-Blind Extension - Week 156: Change From Baseline in HIV RNA (log10 Copies/mL) [units: HIV RNA (log10 copies/mL)] Mean (95% Confidence Interval)	**-1.44 (-1.60 to -1.28)**	**-0.51 (-0.67 to -0.34)**

No statistical analysis provided for Double-Blind Extension - Week 156: Change From Baseline in HIV RNA (log10 Copies/mL)

13. Secondary: Open-Label Extension - Week 240: Change From Baseline in HIV RNA (log10 Copies/mL) [Time Frame: Baseline and Week 240]

Measure Type	Secondary
Measure Title	Open-Label Extension - Week 240: Change From Baseline in HIV RNA (log10 Copies/mL)
Measure Description	Mean change from baseline at Week 240 in HIV RNA (log10 copies/mL)

Time Frame	Baseline and Week 240
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Observed mean change from baseline in log10 plasma HIV RNA calculated using conventional imputation (replace <400 copies by 400 copies if signal detected; 200 copies if not detected); Missing values: baseline carry-forward for all failures/discontinued due to lack of efficacy Participants with virologic failure after Week 16 = treatment failures

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	Raltegravir 400 mg b.i.d plus OBT includes all participants initially randomized to raltegravir. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants continued to receive raltegravir plus OBT until Week 240.
Placebo + OBT	Placebo plus OBT includes all participants initially randomized to placebo. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants received raltegravir plus OBT until Week 240.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	**Placebo + OBT**
Number of Participants Analyzed [units: participants]	**188**	**100**
Open-Label Extension - Week 240: Change From Baseline in HIV RNA (log10 Copies/mL) [units: HIV RNA (log10 copies/mL)] Mean (95% Confidence Interval)	**-1.24 (-1.42 to -1.07)**	**-0.45 (-0.62 to -0.27)**

No statistical analysis provided for Open-Label Extension - Week 240: Change From Baseline in HIV RNA (log10 Copies/mL)

14. Secondary: Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 16 [Time Frame: Baseline and Week 16]

Measure Type	Secondary
Measure Title	Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 16
Measure Description	Mean change from baseline at Week 16 in CD4 Cell Count (cells/mm^3)
Time Frame	Baseline and Week 16
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Observed failure approach assuming baseline-carry-forward for all failures, exclude other missing values. Baseline CD4 cell count (cells/mm^3) was carried forward for participants who discontinued assigned therapy due to lack of efficacy.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.
Placebo + OBT	No text entered.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	Placebo + OBT
Number of Participants Analyzed [units: participants]	**231**	**118**
Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 16 [units: CD4 Cell Count (cells/mm^3)] Mean (95% Confidence Interval)	**82.7 (70.5 to 94.9)**	**31.3 (17.8 to 44.8)**

No statistical analysis provided for Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 16

15. Secondary: Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 48 [Time Frame: Baseline and Week 48]

Measure Type	Secondary
Measure Title	Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 48
Measure Description	Mean change from baseline at Week 48 in CD4 Cell Count (cells/mm^3)
Time Frame	Baseline and Week 48
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Observed failure approach assuming baseline-carry-forward for all failures, exclude other missing values. Baseline CD4 cell count (cells/mm^3) was carried forward for participants who discontinued assigned therapy due to lack of efficacy. Participants with virologic failure after Week 16 are treatment failures for virologic efficacy analyses.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.
Placebo + OBT	No text entered.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	Placebo + OBT
Number of Participants Analyzed [units: participants]	**230**	**119**

Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 48 **[units: CD4 Cell Count (cells/mm^3)]** **Mean (95% Confidence Interval)**	**120.2 (102.2 to 138.1)**	**49.4 (30.4 to 68.5)**

No statistical analysis provided for Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 48

16. Secondary: Double-Blind Extension - Week 156: Change From Baseline in CD4 Cell Count (Cells/mm^3) [Time Frame: Baseline and Week 156]

Measure Type	Secondary
Measure Title	Double-Blind Extension - Week 156: Change From Baseline in CD4 Cell Count (Cells/mm^3)
Measure Description	Mean change from baseline at Week 156 in CD4 Cell Count (cells/mm^3)
Time Frame	Baseline and Week 156
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Observed failure approach assuming baseline-carry-forward for all failures, exclude other missing values. Baseline CD4 cell count (cells/mm^3) was carried forward for participants who discontinued assigned therapy due to lack of efficacy. Participants with virologic failure after Week 16 are treatment failures for virologic efficacy analyses.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	No text entered.
Placebo + OBT	No text entered.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	**Placebo + OBT**
Number of Participants Analyzed **[units: participants]**	**207**	**107**
Double-Blind Extension - Week 156: Change From Baseline in CD4 Cell Count (Cells/mm^3) **[units: CD4 Cell Count (cells/mm^3)]** **Mean (95% Confidence Interval)**	**170.9 (144.4 to 197.4)**	**71.03 (46.28 to 95.77)**

No statistical analysis provided for Double-Blind Extension - Week 156: Change From Baseline in CD4 Cell Count (Cells/mm^3)

17. Secondary: Open-Label Extension - Week 240: Change From Baseline in CD4 Cell Count (Cells/mm^3) [Time Frame: Baseline and Week 240]

Measure Type	Secondary

Measure Title	Open-Label Extension - Week 240: Change From Baseline in CD4 Cell Count (Cells/mm^3)
Measure Description	Mean change from baseline at Week 240 in CD4 Cell Count (cells/mm^3)
Time Frame	Baseline and Week 240
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Observed failure approach assuming baseline-carry-forward for all failures, exclude other missing values. Baseline CD4 cell count (cells/mm^3) was carried forward for participants who discontinued assigned therapy due to lack of efficacy. Participants with virologic failure after Week 16 are treatment failures for virologic efficacy analyses.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d. + OBT	Raltegravir 400 mg b.i.d plus OBT includes all participants initially randomized to raltegravir. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants continued to receive raltegravir plus OBT until Week 240.
Placebo + OBT	Placebo plus OBT includes all participants initially randomized to placebo. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants received raltegravir plus OBT until Week 240.

Measured Values

	Raltegravir 400 mg b.i.d. + OBT	**Placebo + OBT**
Number of Participants Analyzed [units: participants]	**186**	**101**
Open-Label Extension - Week 240: Change From Baseline in CD4 Cell Count (Cells/mm^3) [units: CD4 Cell Count (cells/mm^3)] Mean (95% Confidence Interval)	**193.6 (159.1 to 228.0)**	**68.2 (38.2 to 98.2)**

No statistical analysis provided for Open-Label Extension - Week 240: Change From Baseline in CD4 Cell Count (Cells/mm^3)

Serious Adverse Events

Hide Serious Adverse Events

Time Frame	240 Weeks
Additional Description	Adverse events are reported by original treatment group for the entire 240-week study, including double-blind, open-label, and OLPVF phases; 94 of 118 participants in the placebo group also received raltegravir in the open-label or OLPVF phase.

Reporting Groups

	Description
Raltegravir 400 mg b.i.d Plus OBT	Includes all participants initially randomized to raltegravir, including those without virologic failure who continued into the open-label phase at Week 156 and those who entered the OLPVF phase due to virologic

	failure. During either open-label phase up to Week 240, these participants continued to receive raltegravir 400 mg b.i.d. plus OBT.
Placebo Plus OBT	Includes all participants initially randomized to placebo, including those without virologic failure who continued into the open-label phase at Week 156 and those who entered the OLPVF phase due to virologic failure. During either open-label phase up to Week 240, these participants continued to receive raltegravir 400 mg b.i.d. plus OBT.

Serious Adverse Events

	Raltegravir 400 mg b.i.d Plus OBT	Placebo Plus OBT
Total, serious adverse events		
# participants affected / at risk	**97/232 (41.81%)**	**46/118 (38.98%)**
Blood and lymphatic system disorders		
Anaemia † [1]		
# participants affected / at risk	**2/232 (0.86%)**	**0/118 (0.00%)**
# events	**2**	**0**
Haemolytic anaemia † [1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Haemolytic uraemic syndrome † [1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Leukopenia † [1]		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**2**
Neutropenia † [1]		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Splenic vein thrombosis † [1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Cardiac disorders		
Acute coronary syndrome † [1]		
# participants affected / at risk	**2/232 (0.86%)**	**0/118 (0.00%)**
# events	**2**	**0**
Acute myocardial infarction † [1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Angina pectoris † [1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Angina unstable † [1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Cardiac arrest † [1]		

# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Cardio-respiratory arrest † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Coronary artery disease † 1		
# participants affected / at risk	1/232 (0.43%)	1/118 (0.85%)
# events	1	1
Intracardiac thrombus † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Myocardial infarction † 1		
# participants affected / at risk	4/232 (1.72%)	2/118 (1.69%)
# events	5	3
Pericarditis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Congenital, familial and genetic disorders		
Phimosis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Ear and labyrinth disorders		
Hypoacusis † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Vertigo † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Endocrine disorders		
Hyperthyroidism † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Myxoedema † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Eye disorders		
Uveitis † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Gastrointestinal disorders		
Abdominal pain † 1		
# participants affected / at risk	2/232 (0.86%)	0/118 (0.00%)
# events	2	0
Anal fissure † 1		

# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Ascites † 1		
# participants affected / at risk	2/232 (0.86%)	0/118 (0.00%)
# events	2	0
Constipation † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Diarrhoea † 1		
# participants affected / at risk	3/232 (1.29%)	0/118 (0.00%)
# events	4	0
Enteritis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Gastric varices † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Gastritis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	2	0
Haemorrhoids † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Hernial eventration † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Inguinal hernia † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Intestinal obstruction † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Intestinal perforation † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Mesenteric vein thrombosis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Oesophagitis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Rectal haemorrhage † 1		
# participants affected / at risk	2/232 (0.86%)	1/118 (0.85%)
# events	2	1
Rectal perforation † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)

# events	0	1
Rectal stenosis † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Umbilical hernia † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Upper gastrointestinal haemorrhage † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Varices oesophageal † 1		
# participants affected / at risk	2/232 (0.86%)	0/118 (0.00%)
# events	2	0
General disorders		
Asthenia † 1		
# participants affected / at risk	2/232 (0.86%)	1/118 (0.85%)
# events	2	1
Chest pain † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Malaise † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Multi-organ failure † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Oedema peripheral † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Pyrexia † 1		
# participants affected / at risk	3/232 (1.29%)	3/118 (2.54%)
# events	3	11
Soft tissue inflammation † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Hepatobiliary disorders		
Cholangitis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Gallbladder disorder † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Hepatitis † 1		
# participants affected / at risk	2/232 (0.86%)	0/118 (0.00%)
# events	3	0

Hepatitis toxic † 1		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Portal hypertension † 1		
# participants affected / at risk	**2/232 (0.86%)**	**0/118 (0.00%)**
# events	**2**	**0**
Portal vein thrombosis † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Immune system disorders		
Drug hypersensitivity † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Hypersensitivity † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**2**	**0**
Infections and infestations		
Anogenital warts † 1		
# participants affected / at risk	**2/232 (0.86%)**	**0/118 (0.00%)**
# events	**2**	**0**
Appendicitis † 1		
# participants affected / at risk	**2/232 (0.86%)**	**0/118 (0.00%)**
# events	**2**	**0**
Bone tuberculosis † 1		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Bronchopneumonia † 1		
# participants affected / at risk	**2/232 (0.86%)**	**0/118 (0.00%)**
# events	**2**	**0**
Candidiasis † 1		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Carbuncle † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Cellulitis † 1		
# participants affected / at risk	**2/232 (0.86%)**	**0/118 (0.00%)**
# events	**2**	**0**
Choriomeningitis lymphocytic † 1		
# participants affected / at risk	**2/232 (0.86%)**	**0/118 (0.00%)**
# events	**2**	**0**
Cytomegalovirus chorioretinitis † 1		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Cytomegalovirus colitis † 1		

# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Cytomegalovirus hepatitis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Cytomegalovirus infection † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Diarrhoea infectious † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Disseminated cytomegaloviral infection † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Dysentery † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
End stage AIDS † 1		
# participants affected / at risk	1/232 (0.43%)	1/118 (0.85%)
# events	1	1
Endophthalmitis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	2	0
Epidermodysplasia verruciformis † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Erythema infectiosum † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Fallopian tube abscess † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Gastroenteritis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Gastroenteritis viral † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Genital herpes † 1		
# participants affected / at risk	3/232 (1.29%)	0/118 (0.00%)
# events	3	0
Giardiasis † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
HIV infection † 1		

# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Influenza † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Leishmaniasis † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	4
Lower respiratory tract infection † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Meningitis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Meningitis cryptococcal † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Mycobacterial infection † 1		
# participants affected / at risk	2/232 (0.86%)	0/118 (0.00%)
# events	2	0
Mycobacterium avium complex infection † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Oesophageal candidiasis † 1		
# participants affected / at risk	1/232 (0.43%)	3/118 (2.54%)
# events	1	3
Oral candidiasis † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Pharyngitis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Pneumocystis jiroveci pneumonia † 1		
# participants affected / at risk	2/232 (0.86%)	0/118 (0.00%)
# events	2	0
Pneumonia † 1		
# participants affected / at risk	11/232 (4.74%)	5/118 (4.24%)
# events	11	6
Pneumonia fungal † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Pneumonia pneumococcal † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Progressive multifocal leukoencephalopathy † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)

# events	0	1
Pseudomonal sepsis † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Respiratory tract infection † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Sepsis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Septic shock † 1		
# participants affected / at risk	2/232 (0.86%)	1/118 (0.85%)
# events	3	2
Sinusitis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Staphylococcal bacteraemia † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Subcutaneous abscess † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Syphilis † 1		
# participants affected / at risk	1/232 (0.43%)	1/118 (0.85%)
# events	1	1
Tuberculosis of genitourinary system † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Urinary tract infection † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Urosepsis † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Varicella † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Visceral leishmaniasis † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Injury, poisoning and procedural complications		
Accidental overdose † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Fibula fracture † 1		

# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Foot fracture † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Humerus fracture † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Incisional hernia † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Inflammation of wound † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Intentional overdose † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Jaw fracture † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Lower limb fracture † 1		
# participants affected / at risk	2/232 (0.86%)	0/118 (0.00%)
# events	2	0
Overdose † 1		
# participants affected / at risk	1/232 (0.43%)	2/118 (1.69%)
# events	1	2
Post procedural haematuria † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Skull fracture † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Spinal fracture † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Subdural haematoma † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Tendon rupture † 1		
# participants affected / at risk	2/232 (0.86%)	0/118 (0.00%)
# events	2	0
Thoracic vertebral fracture † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	3
Tibia fracture † 1		

# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Toxicity to various agents † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Wrist fracture † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Investigations		
Alanine aminotransferase increased † 1		
# participants affected / at risk	2/232 (0.86%)	0/118 (0.00%)
# events	2	0
Aspartate aminotransferase increased † 1		
# participants affected / at risk	2/232 (0.86%)	0/118 (0.00%)
# events	2	0
Blood potassium decreased † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Neutrophil count decreased † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	3	0
Weight decreased † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Metabolism and nutrition disorders		
Diabetes mellitus † 1		
# participants affected / at risk	1/232 (0.43%)	1/118 (0.85%)
# events	2	1
Diabetic complication † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Diabetic foot † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	2	0
Hypoglycaemia † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Malnutrition † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Metabolic acidosis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Obesity † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)

# events	0	1
Musculoskeletal and connective tissue disorders		
Intervertebral disc protrusion † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Muscular weakness † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Musculoskeletal pain † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Osteonecrosis † 1		
# participants affected / at risk	3/232 (1.29%)	0/118 (0.00%)
# events	3	0
Osteoporotic fracture † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Anal cancer † 1		
# participants affected / at risk	3/232 (1.29%)	1/118 (0.85%)
# events	3	1
B-cell lymphoma † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Basal cell carcinoma † 1		
# participants affected / at risk	5/232 (2.16%)	3/118 (2.54%)
# events	8	3
Bowen's disease † 1		
# participants affected / at risk	2/232 (0.86%)	0/118 (0.00%)
# events	2	0
Colon cancer † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Colon cancer metastatic † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Colorectal cancer † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Colorectal cancer metastatic † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Colorectal cancer recurrent † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)

# events	1	0
Diffuse large B-cell lymphoma † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Hodgkin's disease † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Kaposi's sarcoma AIDS related † 1		
# participants affected / at risk	4/232 (1.72%)	0/118 (0.00%)
# events	4	0
Lip neoplasm malignant stage unspecified † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Lung neoplasm malignant † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Lymphoma † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Non-Hodgkin's lymphoma † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Oral neoplasm † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Rectal cancer † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Skin cancer † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Squamous cell carcinoma † 1		
# participants affected / at risk	2/232 (0.86%)	3/118 (2.54%)
# events	5	5
Squamous cell carcinoma of skin † 1		
# participants affected / at risk	2/232 (0.86%)	0/118 (0.00%)
# events	2	0
T-cell lymphoma † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Tongue neoplasm malignant stage unspecified † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Vulval cancer stage 0 † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1

Nervous system disorders		
Cerebral haemorrhage † 1		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Cerebral infarction † 1		
# participants affected / at risk	**1/232 (0.43%)**	**1/118 (0.85%)**
# events	**1**	**1**
Cerebral ischaemia † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Cerebrovascular accident † 1		
# participants affected / at risk	**2/232 (0.86%)**	**1/118 (0.85%)**
# events	**3**	**1**
Convulsion † 1		
# participants affected / at risk	**1/232 (0.43%)**	**2/118 (1.69%)**
# events	**1**	**3**
Encephalitis † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Epilepsy † 1		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**4**
Hydrocephalus † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Hypoaesthesia † 1		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Ischaemic stroke † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Parkinsonism † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Poor quality sleep † 1		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Psychomotor hyperactivity † 1		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Syncope † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Psychiatric disorders		
† 1		

Depression		
# participants affected / at risk	**0/232 (0.00%)**	**2/118 (1.69%)**
# events	**0**	**3**
Disturbance in social behaviour [† 1]		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Panic attack [† 1]		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Psychotic disorder [† 1]		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Substance abuse [† 1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Suicide attempt [† 1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Renal and urinary disorders		
Calculus urinary [† 1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Focal segmental glomerulosclerosis [† 1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Nephrolithiasis [† 1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Nephropathy [† 1]		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Nephropathy toxic [† 1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Nephrotic syndrome [† 1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Proteinuria [† 1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Renal failure [† 1]		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Renal failure acute [† 1]		
# participants affected / at risk	**2/232 (0.86%)**	**0/118 (0.00%)**

# events	2	0
Renal tubular necrosis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Reproductive system and breast disorders		
Benign prostatic hyperplasia † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Epididymal cyst † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Epididymitis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Gynaecomastia † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Oedema genital † 1		
# participants affected / at risk	0/232 (0.00%)	1/118 (0.85%)
# events	0	1
Ovarian necrosis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Prostatitis † 1		
# participants affected / at risk	2/232 (0.86%)	1/118 (0.85%)
# events	2	1
Uterine prolapse † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Respiratory, thoracic and mediastinal disorders		
Dyspnoea † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Haemoptysis † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Hiccups † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0
Lung disorder † 1		
# participants affected / at risk	1/232 (0.43%)	1/118 (0.85%)
# events	1	1
Pneumonia aspiration † 1		
# participants affected / at risk	1/232 (0.43%)	0/118 (0.00%)
# events	1	0

Pneumothorax † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Pulmonary embolism † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Pulmonary hypertension † 1		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Respiratory distress † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Skin and subcutaneous tissue disorders		
Hidradenitis † 1		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**3**
Rash † 1		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Vascular disorders		
Deep vein thrombosis † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Hypotension † 1		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Hypovolaemic shock † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Shock † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**
Varicophlebitis † 1		
# participants affected / at risk	**0/232 (0.00%)**	**1/118 (0.85%)**
# events	**0**	**1**
Venous thrombosis † 1		
# participants affected / at risk	**1/232 (0.43%)**	**0/118 (0.00%)**
# events	**1**	**0**

† Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 14.0

Other Adverse Events

Hide Other Adverse Events

Time Frame	240 Weeks
Additional Description	Adverse events are reported by original treatment group for the entire 240-week study, including double-blind, open-label, and OLPVF phases; 94 of 118 participants in the placebo group also received raltegravir in the open-label or OLPVF phase.

Frequency Threshold

Threshold above which other adverse events are reported	5%

Reporting Groups

	Description
Raltegravir 400 mg b.i.d Plus OBT	Includes all participants initially randomized to raltegravir, including those without virologic failure who continued into the open-label phase at Week 156 and those who entered the OLPVF phase due to virologic failure. During either open-label phase up to Week 240, these participants continued to receive raltegravir 400 mg b.i.d. plus OBT.
Placebo Plus OBT	Includes all participants initially randomized to placebo, including those without virologic failure who continued into the open-label phase at Week 156 and those who entered the OLPVF phase due to virologic failure. During either open-label phase up to Week 240, these participants continued to receive raltegravir 400 mg b.i.d. plus OBT.

Other Adverse Events

	Raltegravir 400 mg b.i.d Plus OBT	**Placebo Plus OBT**
Total, other (not including serious) adverse events		
# participants affected / at risk	**206/232 (88.79%)**	**104/118 (88.14%)**
Blood and lymphatic system disorders		
Anaemia † [1]		
# participants affected / at risk	**9/232 (3.88%)**	**7/118 (5.93%)**
# events	**12**	**13**
Lymphadenopathy † [1]		
# participants affected / at risk	**19/232 (8.19%)**	**5/118 (4.24%)**
# events	**19**	**8**
Gastrointestinal disorders		
Abdominal pain † [1]		
# participants affected / at risk	**15/232 (6.47%)**	**11/118 (9.32%)**
# events	**16**	**12**
Diarrhoea † [1]		
# participants affected / at risk	**74/232 (31.90%)**	**34/118 (28.81%)**
# events	**110**	**70**
Gastritis † [1]		
# participants affected / at risk	**8/232 (3.45%)**	**7/118 (5.93%)**
# events	**8**	**8**
Haemorrhoids † [1]		
# participants affected / at risk	**12/232 (5.17%)**	**2/118 (1.69%)**
# events	**12**	**2**
Nausea † [1]		

# participants affected / at risk	30/232 (12.93%)	20/118 (16.95%)
# events	38	25
Vomiting † 1		
# participants affected / at risk	18/232 (7.76%)	17/118 (14.41%)
# events	26	25
General disorders		
Asthenia † 1		
# participants affected / at risk	15/232 (6.47%)	11/118 (9.32%)
# events	16	11
Fatigue † 1		
# participants affected / at risk	18/232 (7.76%)	6/118 (5.08%)
# events	18	9
Injection site reaction † 1		
# participants affected / at risk	18/232 (7.76%)	14/118 (11.86%)
# events	19	16
Pyrexia † 1		
# participants affected / at risk	28/232 (12.07%)	18/118 (15.25%)
# events	35	23
Infections and infestations		
Anogenital warts † 1		
# participants affected / at risk	11/232 (4.74%)	6/118 (5.08%)
# events	14	7
Bronchitis † 1		
# participants affected / at risk	42/232 (18.10%)	16/118 (13.56%)
# events	71	23
Gastroenteritis † 1		
# participants affected / at risk	22/232 (9.48%)	3/118 (2.54%)
# events	28	4
Genital herpes † 1		
# participants affected / at risk	10/232 (4.31%)	9/118 (7.63%)
# events	11	12
Herpes simplex † 1		
# participants affected / at risk	12/232 (5.17%)	3/118 (2.54%)
# events	13	6
Herpes zoster † 1		
# participants affected / at risk	20/232 (8.62%)	7/118 (5.93%)
# events	23	10
Influenza † 1		
# participants affected / at risk	25/232 (10.78%)	8/118 (6.78%)
# events	28	11
Nasopharyngitis † 1		
# participants affected / at risk	58/232 (25.00%)	21/118 (17.80%)
# events	96	51
Oral candidiasis † 1		
# participants affected / at risk	11/232 (4.74%)	15/118 (12.71%)

# events	14	20
Pharyngitis † 1		
# participants affected / at risk	15/232 (6.47%)	8/118 (6.78%)
# events	24	11
Pneumonia † 1		
# participants affected / at risk	9/232 (3.88%)	9/118 (7.63%)
# events	12	11
Respiratory tract infection † 1		
# participants affected / at risk	19/232 (8.19%)	3/118 (2.54%)
# events	21	5
Sinusitis † 1		
# participants affected / at risk	11/232 (4.74%)	6/118 (5.08%)
# events	15	13
Upper respiratory tract infection † 1		
# participants affected / at risk	20/232 (8.62%)	7/118 (5.93%)
# events	35	15
Urinary tract infection † 1		
# participants affected / at risk	14/232 (6.03%)	6/118 (5.08%)
# events	17	8
Investigations		
Alanine aminotransferase increased † 1		
# participants affected / at risk	24/232 (10.34%)	9/118 (7.63%)
# events	40	19
Aspartate aminotransferase increased † 1		
# participants affected / at risk	24/232 (10.34%)	8/118 (6.78%)
# events	30	18
Blood cholesterol increased † 1		
# participants affected / at risk	28/232 (12.07%)	9/118 (7.63%)
# events	44	20
Blood triglycerides increased † 1		
# participants affected / at risk	22/232 (9.48%)	11/118 (9.32%)
# events	30	14
Weight decreased † 1		
# participants affected / at risk	6/232 (2.59%)	7/118 (5.93%)
# events	8	7
Metabolism and nutrition disorders		
Decreased appetite † 1		
# participants affected / at risk	12/232 (5.17%)	6/118 (5.08%)
# events	13	6
Diabetes mellitus † 1		
# participants affected / at risk	6/232 (2.59%)	6/118 (5.08%)
# events	7	6
Musculoskeletal and connective tissue disorders		
Arthralgia † 1		
# participants affected / at risk	14/232 (6.03%)	7/118 (5.93%)

# events	15	8
Back pain † 1		
# participants affected / at risk	26/232 (11.21%)	10/118 (8.47%)
# events	33	14
Muscle spasms † 1		
# participants affected / at risk	12/232 (5.17%)	7/118 (5.93%)
# events	15	7
Myalgia † 1		
# participants affected / at risk	9/232 (3.88%)	8/118 (6.78%)
# events	9	9
Pain in extremity † 1		
# participants affected / at risk	12/232 (5.17%)	6/118 (5.08%)
# events	16	6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Skin papilloma † 1		
# participants affected / at risk	16/232 (6.90%)	6/118 (5.08%)
# events	20	8
Nervous system disorders		
Dizziness † 1		
# participants affected / at risk	14/232 (6.03%)	2/118 (1.69%)
# events	15	2
Headache † 1		
# participants affected / at risk	28/232 (12.07%)	24/118 (20.34%)
# events	38	29
Psychiatric disorders		
Depression † 1		
# participants affected / at risk	13/232 (5.60%)	9/118 (7.63%)
# events	14	10
Insomnia † 1		
# participants affected / at risk	24/232 (10.34%)	12/118 (10.17%)
# events	24	14
Respiratory, thoracic and mediastinal disorders		
Cough † 1		
# participants affected / at risk	20/232 (8.62%)	11/118 (9.32%)
# events	24	14
Skin and subcutaneous tissue disorders		
Eczema † 1		
# participants affected / at risk	6/232 (2.59%)	7/118 (5.93%)
# events	7	7
Lipodystrophy acquired † 1		
# participants affected / at risk	11/232 (4.74%)	6/118 (5.08%)
# events	11	6
Pruritus † 1		

# participants affected / at risk	**16/232 (6.90%)**	**6/118 (5.08%)**
# events	**20**	**6**
Rash † 1		
# participants affected / at risk	**20/232 (8.62%)**	**7/118 (5.93%)**
# events	**25**	**12**
Vascular disorders		
Hypertension † 1		
# participants affected / at risk	**32/232 (13.79%)**	**12/118 (10.17%)**
# events	**32**	**12**

† Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 14.0

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data

Adverse events are reported by original treatment group for the entire 240-week study, including double-blind, open-label, and OLPVF phases; 94 of 118 participants in the placebo group also received raltegravir in the open-label or OLPVF phase.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are **NOT** employed by the organization sponsoring the study.

There **IS** an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

☐ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is **less than or equal to 60 days**. The sponsor cannot require changes to the communication and cannot extend the embargo.

☐ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is **more than 60 days but less than or equal to 180 days**. The sponsor cannot require changes to the communication and cannot extend the embargo.

☑ Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Restriction Description: Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.

Results Point of Contact:

Name/Title: Senior Vice President, Global Clinical Development
Organization: Merck Sharp & Dohme Corp
phone: 1-800-672-6372
e-mail: ClinicalTrialsDisclosure@merck.com

Publications of Results:

Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002.

Other Publications:

Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975.

Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978.

Responsible Party:	Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:	NCT00293267 History of Changes
Other Study ID Numbers:	**0518-018** 2005_096
Study First Received:	February 14, 2006
Results First Received:	August 18, 2009
Last Updated:	September 4, 2015
Health Authority:	France: Ministry of Health

TO TOP

For Patients and Families | **For Researchers** | **For Study Record Managers**

HOME RSS FEEDS SITE MAP TERMS AND CONDITIONS DISCLAIMER CONTACT NLM HELP DESK